Eli Lilly and Company today announced that Maura Dickler, M.D., a prestigious breast cancer researcher, will join Lilly Oncology as Vice President of Late Phase Development on May 7, 2018.
Dr. Dickler is currently the Section Head, Endocrine Therapy Clinical Research Program at Memorial Sloan Kettering Cancer Center (MSKCC). She concurrently serves as Associate Member, Breast Medicine Service, Department of Medicine, MSKCC and Associate Professor of Medicine, Weill Cornell Medical College, NY. She will report to Levi Garraway, M.D., Ph.D., Senior Vice President, Global Development & Medical Affairs of Lilly Oncology.
“Dr. Dickler is an internationally recognized oncology leader with drug development expertise spanning a wide range of therapeutic modalities,” said Garraway. “Moreover, she is an exceptionally gifted clinician for whom patients are at the center of everything she does. We are thrilled to have Dr. Dickler join us at Lilly.”
About Maura Dickler, M.D.
Dr. Dickler graduated from The University of Chicago’s Pritzker School of Medicine and completed her fellowship at MSKCC. She is a clinical researcher on the Breast Medicine Service at MSKCC, with a research program focused on developing new therapeutic strategies for the treatment of women with hormone-receptor positive (HR+) breast cancer. She has led clinical trials investigating therapeutic agents targeting several growth factor receptor-signaling pathways important in breast cancer, including the epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), vascular endothelial growth factor receptor (VEGFR), phosphoinositide 3-kinase (PI3K) and the estrogen receptor pathway. She has also investigated cyclin-dependent kinase 4 & 6 (CDK4 & 6) inhibitors targeting the cell cycle.
Dr. Dickler’s research and clinical accomplishments have led to numerous publications and she has served on various committees including the Breast Committee of The Alliance for Clinical Trials in Oncology. She has received honors for her clinical care, including New York Magazine’s Best Doctors, Medical Oncology in 2015, 2016 and 2017; Castle Connolly America’s Top Doctors; and Castle Connolly Exceptional Women in Medicine in 2017.
Source: Eli Lilly and Company
The company plans to pour more than $500 million in additional funds into its active pharmaceutical ingredient (API) plant in Raheen, Limerick County, the country’s Industrial Development Agency (IDA) said. The new funding brings the company’s total investment in the site to 927 million euros ($1 billion).
“If in 2005 someone told you that two-thirds of our industry would be driven on the R&D side by emerging biopharma—it would be unthinkable. If one were to project that trend forward, what it would suggest is that we could have a day when we do this talk, say in 2027 or 2028, where 80% of the industry’s pipeline is coming from emerging companies.”
The German healthcare and agrochemicals giant told Reuters that in future its pharma pipeline will focus on cardiovascular disease, neurology, rare diseases and immunology, while de-emphasizing women’s health, a field it first focused on with the acquisition of the former women’s health specialist Schering in 2006.
